Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 10/20 | 0.61 |
| ▸ | UBE2M | P61081 | 9/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200025 | 0.96 | UBE2M (0.60) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23200048 | 0.95 | ALDH1A1 (0.61) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23199936 | 0.89 | UBE2M (0.54) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23699905 | 0.86 | UBE2M (0.51) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23699895 | 0.84 | LMNA (0.56) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23699911 | 0.84 | GAA (0.55) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23200222 | 0.84 | LMNA (0.51) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23200154 | 0.83 | LMNA (0.50) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23200139 | 0.83 | GAA (0.54) | DCUN1D1UBE2MLMNAALDH1A1GAA | |
| SCHEMBL23200204 | 0.83 | LMNA (0.50) | DCUN1D1UBE2MLMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | claimed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | DCUN1D1 1039/4885UBE2M 3929/4885LMNA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.